Evommune insider withholds 1,478 shares for RSU tax obligations

Evommune, Inc. reported an insider equity transaction by a director and Chief Medical Officer.

Rhea-AI Filing Summary

Evommune, Inc. reported an insider equity transaction by a director and Chief Medical Officer. On 12/09/2025, the insider had 1,478 shares of common stock withheld at a price of $17.84 per share to cover tax withholding obligations tied to the settlement of restricted stock units. After this tax-related withholding, the insider beneficially owns 270,818 shares of Evommune common stock in direct ownership.

Insider Trade Summary

Exercise Price or Tax Liability: 1,478 shares

Exercise Price or Tax Liability 1 txn

Insider Bauer Eugene

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	1,478	$17.84	$26K

Holdings After Transaction: Common Stock — 270,818 shares (Direct)

Footnotes (1)

1. F1. Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

FAQ

What insider transaction did Evommune (EVMN) disclose in this Form 4?

The disclosure shows that a director and Chief Medical Officer of Evommune, Inc. had 1,478 shares of common stock withheld on 12/09/2025 to satisfy tax withholding obligations related to restricted stock units.

How many Evommune (EVMN) shares were involved in the insider tax withholding?

The insider had 1,478 shares of Evommune common stock withheld at a price of $17.84 per share in connection with RSU settlement taxes.

How many Evommune (EVMN) shares does the insider own after this transaction?

Following the reported transaction, the insider beneficially owns 270,818 shares of Evommune common stock, held as direct ownership.

Was the Evommune (EVMN) insider transaction an open-market sale?

No. The explanation states that the 1,478 shares were withheld to satisfy the insider's tax withholding obligations in connection with the settlement of restricted stock units, rather than an open-market sale.

What is the role of the reporting person at Evommune (EVMN)?

The reporting person is both a director and an officer of Evommune, Inc., serving as the company's Chief Medical Officer.

What transaction code is used for the Evommune (EVMN) insider withholding?

The transaction is coded as "F", which indicates shares were withheld by the issuer to cover the insider's tax obligations upon settlement of equity awards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/11/2025 - 04:18 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bauer Eugene

(Last) (First) (Middle)

C/O EVOMMUNE, INC.

1841 PAGE MILL ROAD, SUITE 100

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Evommune, Inc. [ EVMN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/09/2025		F		1,478(1)	D	$17.84	270,818	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

Remarks:

	/s/ Gregory S. Moss, Attorney-in-Fact	12/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.